Skip to content

5-MeO-DMT: all studies

Page 77 of 110: studies 761 to 770 of 1,097, newest first. Back to the 5-MeO-DMT overview

Research

DMT und Ayahuasca

Suchttherapie May 1, 2021

[ Abb. 1 ] zeigt die Strukturformel, die Anwendungsarten und die handelsüblichen Formen von DMT (Dimethyltryptamin). Substanz Tryptaminhaltige Pflanzen wurden über mehrere 1000 Jahre von südamerikanischen Ureinwohnern bei religiösen Ritualen und zu medizinischen Zwecken eingenommen. Ziel dabei war die Provokation visionärer Erlebnisse als Kontaktaufnahme mit einer jenseitigen Welt, z. B. um die...

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans

Molecules April 22, 2021 Paul Cumming, Milan Scheidegger, Dario Dornbierer et al. 45 citations

Hallucinogens are a loosely defined group of compounds including LSD, N,N-dimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a...

DOI: 10.3390/molecules26092451 (opens in new tab) Action physics Drug action Pharmacology

Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey.

Frontiers in Pharmacology April 21, 2021 Daniel Perkins, Violeta Schubert, Hana Šimonová et al. 73 citations

Ayahuasca is a traditional plant decoction containing N,N-dimethyltryptamine (DMT) and various β-carbolines including harmine, harmaline, and tetrahydroharmine, which has been used ceremonially by Amazonian Indigenous groups for healing and spiritual purposes. Use of the brew has now spread far beyond its original context of consumption to North America, Europe, and Australia in neo-shamanic...

DOI: 10.3389/fphar.2021.623979 (opens in new tab) Full text (opens in new tab) Ayahuasca context Ayahuasca setting Ayahuasca environment Ayahuasca preparation +16

Psychedelics: A new era of treatment?

European Psychiatry April 1, 2021 S. Torres 2 citations

Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to the recreational use in the mid-1960s....

New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.

Journal of Food and Drug Analysis March 15, 2021 Wen-Jing Yu, Linda B. Cottler, Jih-Heng Li 13 citations

Use of New Psychoactive Substances (NPS) has posed a global threat to public health and the security of the population. As of December 2019, the NPS items identified in total have outnumbered by three to one the controlled substances listed in the 1961 and 1971 UN Drug Conventions. However, most of these NPS have not been scheduled by the United Nations because of their easy modification on the...

DOI: 10.38212/2224-6614.3225 (opens in new tab) Full text (opens in new tab) Addiction Psychoactive substances Traditional controlled drugs Drug misuse +11

Baseline power of theta oscillations predicts mystical-type experiences induced by DMT

bioRxiv Preprint Server March 11, 2021 Enzo Tagliazucchi, Federico Zamberlán, Federico Cavanna et al. 3 citations preprint

N,N-Dimethyltryptamine (DMT) is a classic psychedelic capable of inducing short-lasting but profound changes in consciousness. As with other psychedelics, the experience induced by DMT strongly depends upon contextual factors, yet the neurobiological determinants of this variability remain unknown. We combined wireless electroencephalography and source imaging to map changes in neural...

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Hypertension March 8, 2021 Otto Simonsson, Peter S. Hendricks, Robin Carhart-Harris et al. 36 citations

Using data from the National Survey on Drug Use and Health (2005–2014), weighted to be representative of the US adult population, the present study investigated the association between lifetime classic psychedelic use and hypertension in the past year among adults in the United States. The results showed that respondents who reported having used a classic psychedelic at least once in their...

How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence

Anesthesia & Analgesia February 17, 2021 Peter G. Brindley 49 citations

It is tough to write about psychedelics without a few gratuitous puns. Regardless, Michael Pollan’s “How to Change Your Mind” is definitely “mind expanding” and deserves my “highest” recommendation. Published in 2019, this book comprehensively and presciently covers a topic of increasing interest: whether psychedelic agents can revolutionize mental health. Pollan is not a Medical Doctor but is...

DOI: 10.1213/ane.0000000000005349 (opens in new tab) Psilocybin Counterculture Consciousness Psychic +4

Psilocin acutely disrupts sleep and affects local but not global sleep homeostasis in laboratory mice

bioRxiv Preprint Server February 16, 2021 Christopher W. Thomas, Cristina Blanco-Duque, Benjamin J. B. Bréant et al. 4 citations preprint

Serotonergic psychedelic drugs, such as psilocin (4-hydroxy-N,N-dimethyltryptamine), profoundly alter the quality of consciousness through mechanisms which are incompletely understood. Growing evidence suggests that a single psychedelic experience can positively impact long-term psychological well-being, with relevance for the treatment of psychiatric disorders, including depression. A...

Dual actions of 5‐MeO‐DIPT at the serotonin transporter and serotonin 5‐HT1A receptor in the mouse striatum and prefrontal cortex

Neuropsychopharmacology Reports February 6, 2021 Yoko Hagino, F. Scott Hall, George R. Uhl et al. 3 citations

Abstract Aims 5‐Methoxy‐ N , N ‐diisopropyltryptamine (5‐MeO‐DIPT) is a synthetic orally active hallucinogenic tryptamine analogue. The present study examined whether the effects of 5‐MeO‐DIPT involve the serotonin transporter (SERT) and serotonin 5‐hydroxytryptamine‐1A (5‐HT 1A ) receptor in the striatum and prefrontal cortex (PFC). Methods We investigated the effects of 5‐MeO‐DIPT on...

DOI: 10.1002/npr2.12161 (opens in new tab) Striatum 5-HT Receptor Serotonin transporter Dopamine +6